441 related articles for article (PubMed ID: 27520509)
1. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
2. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Namin AW; Christopher KM; Eisenbeis JF
J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life and Voice Changes After a Single Injection in Patients With ADSD Over Time.
Faham M; Torabinezhad F; Murry T; Dabirmoghaddam P; Abolghasemi J; Kamali M; Asgari M
J Voice; 2019 Sep; 33(5):721-727. PubMed ID: 29884509
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
5. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
8. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
[TBL] [Abstract][Full Text] [Related]
9. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
10. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
[TBL] [Abstract][Full Text] [Related]
11. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
12. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
13. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
14. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
16. Sulcus vocalis in spasmodic dysphonia-A retrospective study.
Nerurkar NK; Agrawal D; Joshi D
Am J Otolaryngol; 2021; 42(3):102940. PubMed ID: 33545449
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
18. Current practices in the management of adductor spasmodic dysphonia.
Eskander A; Fung K; McBride S; Hogikyan N
J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
20. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
